Intelligence · Patents
Patents expiring in 2043
Annual patent cliff calendar for 2043 — US pharmaceutical patents by expiration date.
- Patents
- 1,718
Quick answer
1,718 indexed pharmaceutical patents have expiration dates in 2043. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 11801234
Methods of treating APOL-1 dependent focal segmental glomerulosclerosis
granted -
US 11801296
Development of a novel live attenuated African swine fever vaccine based in the deletion of gene A137R
granted -
US 11801313
Materials and methods for treatment of pain related disorders
granted -
US 11801269
Compositions and methods for transplantation of colon microbiota
granted -
US 11802138
Optimized peptides for targeting human nerves and their use in image guided surgery, diagnostic and therapeutic delivery
granted -
US 11801295
Immunogenic compositions and uses thereof
granted -
US 11801241
Muscarinic M2 receptor blockade to delay or prevent onset of progressive memory decline
granted -
US 11801298
MERS-CoV vaccine
granted -
US 11801218
Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine
granted -
US 11801265
Preparation method of NK cells and use thereof in the treatment of cancer
granted -
US 11802131
Glutarimides for medical treatment
granted -
US 11802157
Methods and compositions for modulating CAR-T activity
granted -
US 11802158
Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same
granted -
US 11802272
Enrich and amplify highly potent human mesenchymal stem cells from elderly cell populations
granted -
US 11801257
Stimulation of an immune response by enantiomers of cationic lipids
granted -
US 11801268
Methods of treating ocular inflammation and chemical injuries of the eye with extracellular vesicles
granted -
US 11801288
Cancer vaccines and methods of treatment using the same
granted -
US 11802279
Modified L-asparaginase
granted -
US 11802292
Modified orthopoxvirus vectors
granted -
US 11802110
2-amino-N-(arylsulfinyl)-acetamide compounds as inhibitors of bacterial aminoacyl-tRNA synthetase
granted -
US 11801229
Molecular entrapment via homopolymer self-assembly
granted -
US 11802237
Method for producing powder containing zirconia particles and fluorescent agent
granted -
US 11807682
M971 chimeric antigen receptors
granted -
US 11807853
Soluble interleukin-7 receptor (sIL7R) modulating therapy to treat autoimmune diseases and cancer
granted -
US 11806400
Injectable ibuprofen formulation
granted -
US 11807605
Human plasma kallikrein inhibitors
granted -
US 11806429
Film formulations containing dexmedetomidine and methods of producing them
granted -
US 11806421
Porous-cellulose particles and production method thereof, and cosmetic
granted -
US 11807649
Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2
granted -
US 11806353
Methods of treating liver disorders or lipid disorders with a THR-beta agonist
granted -
US 11806337
Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof
granted -
US 11806408
Methods and compositions for treating cone-rod retinal dystrophy
granted -
US 11807658
CD73 inhibitors
granted -
US 11807638
5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases
granted -
US 11807644
Methods and compounds for restoring mutant p53 function
granted -
US 11807661
Antibody fusion protein and related compositions for targeting cancer
granted -
US 11807689
Anti-CD20 antibody compositions
granted -
US 11807868
Adeno-associated variants, formulations and methods for pulmonary delivery
granted -
US 11807882
Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use
granted -
US 11807674
Hepcidin analogues and uses thereof
granted -
US 11806360
Compositions and methods for treating transthyretin (TTR) mediated amyloidosis
granted -
US 11806367
Methods of treating lysosomal disorders
granted -
US 11806318
Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
granted -
US 11806369
Exosomes and miRNA to treat glaucoma
granted -
US 11806385
Biomarkers for monitoring immune transformation
granted -
US 11806354
Pharmaceutical compositions comprising meloxicam
granted -
US 11806389
Compositions and methods for treating central nervous system injury
granted -
US 11807629
Polymorphs of Selinexor
granted
Frequently asked questions
How many pharma patents expire in 2043?
1,718 published patents in our USPTO index have expiration dates falling in calendar year 2043.